Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totaling 489,633 shares, an increase of 77.6% from the April 15th total of 275,689 shares. Based on an average daily volume of 681,214 shares, the days-to-cover ratio is currently 0.7 days. Currently, 8.6% of the company’s stock are sold short.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ALGS. Rockefeller Capital Management L.P. grew its position in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after acquiring an additional 9,000 shares in the last quarter. NorthCrest Asset Manangement LLC acquired a new position in shares of Aligos Therapeutics in the 3rd quarter worth approximately $98,000. Susquehanna International Group LLP acquired a new position in shares of Aligos Therapeutics in the 3rd quarter worth approximately $99,000. XTX Topco Ltd acquired a new position in shares of Aligos Therapeutics in the 2nd quarter worth approximately $100,000. Finally, HRT Financial LP acquired a new position in shares of Aligos Therapeutics in the 4th quarter worth approximately $106,000. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Price Performance

Shares of NASDAQ ALGS opened at $5.71 on Monday. Aligos Therapeutics has a fifty-two week low of $5.12 and a fifty-two week high of $13.69. The business has a 50 day moving average price of $7.02 and a two-hundred day moving average price of $8.01. The firm has a market cap of $35.34 million, a PE ratio of -0.66 and a beta of 2.28.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The firm had revenue of $2.83 million during the quarter, compared to analyst estimates of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. On average, analysts anticipate that Aligos Therapeutics will post -7.54 earnings per share for the current year.

Analysts Set New Price Targets

ALGS has been the subject of a number of recent analyst reports. Westpark Capital initiated coverage on Aligos Therapeutics in a research note on Thursday, March 26th. They set a “buy” rating and a $48.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a research note on Wednesday, March 11th. Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings restated a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Monday, April 20th. Finally, Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $41.50.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.